Page 17 - 2018_16.3_Neat

LA IMPORTANCIA DE LOS FACTORES SOCIOCULTURALES EN EL ESTUDIO DEL CÁNCER DE CUELLO UTERINO
EN LA ERA DE LA MEDICINA MOLECULAR. UN ENFOQUE DESDE LA TEORÍA DE GÉNERO

Referencias bibliográficas

1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, 12. Wagoner S. E. Cervical Cáncer.
Mathers C, Rebelo M. et.al. Cancer incidence Lancet. 2003; 361: 2217-2225.
and mortality worldwide: Sources, methods 13. Peirson L, Fitzpatrick-Lewis D, Ciliska
and major patterns in GLOBOCAN 2012. D, Warren R. Screening for cervical
Int. J. Cancer: (2015); 136: E359–E386. cancer: a systematic review and meta-
2. Harper DM, Franco EL, Wheeler C, Ferris DG, analysis. Systematic Reviews 2013, 2:35.
Jenkis D, Schuind A et al. Efficacy of bivalent 14. Lörincz AT. Screening for cervical cancer:
L1 virus-like particle vaccine in prevention of New alternatives and research. Salud
infection with human papillomavirus types Pública Mex. 2003; 45, (Supl. 3):S376-87.
16 and 18 in young women: a randomised
controlled trial. Lancet. 2004;364: 1757-65. 15. Markowitz EL, Dunne FE, Saraiya M,
Lawson WH, Chesson H, Unger R. E.
3. Rambout L, Hopkins L, Hutton B, Quadrivalent Human Papillomavirus
Fergusson D. CMAJ. 2007; 177(5): 469-79. Vaccine Recommendations of the
4. Saslow D, Castle PE, Cox J.T, Davey DD, Advisory Committee on Immunization
Einstein MH, Ferris DG, et al. American Practices (ACIP). MMWR CDC Suveill
Cancer Society guideline for human Summ. 2007;56(RR-2), 32pp.
pillomavirus (VPH) vaccine use to prevent 16. Pollack A E, Balkin M, Edouard L, Cutts DF,
cervical cancer and its precursors. Broutet N. Policy and practice. Ensuring
CA Cancer J clin. 2007; 57: 7-28. access to HPV vaccines through integrated
5. Mann L, Foley KL, Tanner AE, Sun CJ, services:a reproductive health perspective.
Rhodes SD. Increasing Cervical Cancer Bull. World Health Organ. 2007;85:57-63.
Screening Among U Hispanics/Latinas: A 17. Palacio-Mejía L.S., Range-Gómez G.,
Qualitative Systematic Review. J Cancer Hernández-Ávila M, Lazcano-Ponce E.
Educ. 2015 June ; 30(2): 374–387. Cervical cancer a disease of poverty:
6. Dirección General de Información en Salud Mortality differences between urban
(DGIS). Cubo de defunciones. [base de datos and rural areas in Mexico. Salud
en internet]. México: Sistema Nacional de Publica Mex. 2003; 45(S3):s315-S325.
Información en Salud (SINAIS); Secretaría de 18. Instituto Nacional de Salud Pública.
Salud; 2012 [en línea] Disponible en: http:// Encuesta Nacional de Salud y Nutrición
pda.salud.gob.mx/cubos/cmortalidad2012. 2012. Resultados Nacionales. México:
html, [Consulta: 01 diciembre 2014]. Instituto Nacional de Salud Pública; 2012.
7. Kousky LA, Ault KA, Wheeler CM, Brown 19. Flores Y, Bishai D, Lazcano E, Shah K, Lörincz
DR, Barr E, Álvarez FB, et al. A controlled A, Hernández M, Salmerón J. Improving
trial of a human papilloma virus Type 16 cervical cancer screening in Mexico:
vaccine. N Engl J Med. 2002;347:1645-1651. Results from the Morelos HPV Study. Salud
8. Bosch FX. Epidemiology of human Pública Mex. 2003; 45(S3):S388-S398.
papiloma virus infections: New optios for 20. Society of Gynecologic Oncologists Education
cervical cancer prevention. Salud Pública Resource Panel. Cervical cancer prevention
Mex. 2003 vol. 45; (Supl. 3):s327-s339. in the era of prophylactic vaccines: A
9. Moreno V, Bosh FX, Muñoz N, Meijer CJLM, preview for gynaecologic oncologists.
Shah KV, Walboomers JMM, et al. Effect of Gynecologic Oncology 2006; 102; 552-562.
oral contraceptives on risk of cervical cancer 21. Lehtinen M, Pavoneen J. Vaccination
in women with human papillomavirus against human papillomaviruses shows
infection: the IARC multicentric case- great promises. Lancet. 2004;364:1731.
control study. Lancet. 2002; 359: 1085-1092. 22. García-Carrancá A. Vaccines against human
10. Muñoz N, Franceschi S, Bosseti C, Moreno pipllomavirus and perspectives for the
V, Herrero R, Smith JS, et al. Role of parity prevention and control of cervical cancer.
and human papillomavirus in cervical Salud Pública Mex. 2003;45 (Supl3):S437-S442.
cancer : The IARC multicentric case
control study. Lancet. 2002;359:1093-1101. 23. Pichon-Riviere A, Alcaraz A, Caporale
J,Bardach A, Rey-Ares L, Klein K.
11. Smith JS, Green J, Berrington de et.al. Costo-efectividad de la vacuna
Gonzalez A, Appleby P, Peto J, Plummer tetravalente contra VPH en Argentina,
M, et al. Cervical cancer and the use of a partir de un modelo dinámico de
hormonal contraceptives: a systematic transmisión. Salud Pública Mex 2015.
review. Lancet. 2003; 361:1159-67.

17